安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Clinical Trial Endpoint Technology and Evidence Generation | Clario
Clario, a part of Thermo Fisher Scientific, combines science-informed endpoint technology, global scale, and expert services to generate reliable clinical evidence for every trial phase
- ERT - The Clario Global Account
The Clario Global Account Please use your verified Clario Global Account and valid password to log in to the Clario portals Note: This account is usually your individual email address Your email address must belong only to you Shared email addresses cannot be used for the Clario portals accounts due to regulatory requirements
- Clario - Wikipedia
In October 2025, Thermo Fisher Scientific announced a deal to acquire Clario for $8 88 billion in cash from a shareholder group including Novo Holding The transaction was expected to close mid-2026
- Clario - LinkedIn
Clario | 138,869 followers on LinkedIn Clario, part of Thermo Fisher Scientific, is a leading provider of endpoint data solutions to the life sciences industry
- Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Completes . . .
Clario integrates clinical trial endpoint data from devices, sites and patients, enabling customers to collect, manage and analyze clinical evidence digitally across every phase of drug development, supporting faster, more confident trial decisions
- Clario – Global Single Sign-On (GSSO)
Clario has upgraded to a new, more secure login system called Global Single Sign-On (GSSO) This change will make it easier and safer for you to access your Clario applications
- Thermo Fisher to buy clinical services provider Clario for up to $9. 4 . . .
Philadelphia-based Clario provides expertise in clinical trial research, using its suite of specialized tools and services to capture, analyze, and validate these studies
- Thermo Fisher to acquire Clario in $9. 4bn deal
Clario, which was founded in 2021 following the merger of health tech firms ERT and Bioclinica, is the third company acquired by Thermo Fisher this year, as the company expands its portfolio amid renewed demand from pharmaceutical firms increasing drug development and manufacturing in the US
|
|
|